West Pharmaceutical Services (STU:WPS) Margin of Safety % (DCF Earnings Based) : -55.92% (As of Dec. 11, 2024)

View and export this data going back to 2016. Start your Free Trial

What is West Pharmaceutical Services Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2024-12-11), West Pharmaceutical Services's Predictability Rank is 2.5-Stars. West Pharmaceutical Services's intrinsic value calculated from the Discounted Earnings model is €193.50 and current share price is €301.70. Consequently,

West Pharmaceutical Services's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is -55.92%.

Competitive Comparison of West Pharmaceutical Services's Margin of Safety % (DCF Earnings Based)

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

West Pharmaceutical Services's Margin of Safety % (DCF Earnings Based) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's Margin of Safety % (DCF Earnings Based) falls into.

West Pharmaceutical Services Margin of Safety % (DCF Earnings Based) Calculation

West Pharmaceutical Services's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)	=	(Intrinsic Value: DCF (Earnings Based)	-	Current Price)	/	Intrinsic Value: DCF (Earnings Based)
	=	(193.50	-	301.70)	/	193.50
	=	-55.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

West Pharmaceutical Services Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

West Pharmaceutical Services Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (STU:WPS) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

WST:USA WST:Mexico WPS:Germany W2ST34:Brazil

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-1147

Website

https://www.westpharma.com

West Pharmaceutical Services is based in Pennsylvania, us, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.